Nika Pharmaceuticals, Inc. Overview
Pro stress-test →Nika Pharmaceuticals (OTCQB: NIKA) is a biopharmaceutical company developing advanced immune-strengthening therapeutics for HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes. The company's intellectual property portfolio includes six injectable drugs, four oral formulations, and eleven dietary supplements.
Strategic Profile
Pro stress-test →Two injectable candidates have successfully completed clinical trials with strong efficacy and safety results, positioning NIKA for advancement into broader commercialization efforts. The company projects €8.5 Billion revenue from its distribution agreements for Nigeria, Ukraine, UAE, Iraq, Syria, and Jordan. The company combines clinical innovation with a mission-driven approach to global healthcare accessibility.
Competitive Landscape
Pro stress-test →Nika competes in the broader biotech immunology and nutraceuticals space against established pharmaceutical companies developing immune-modulation therapies. Key competitive dynamics center on clinical validation, manufacturing capability, and distribution access in emerging markets. The company's OTC status and early-stage pipeline position it as a micro-cap player rather than a direct competitor to large-cap pharma.
Industry Context
Nika Pharmaceuticals, Inc. operates in Biopharmaceuticals & Immunology.
Key facts
Founded: 2000 · Headquarters: Henderson, Nevada, US · Employees: N/A · Revenue: N/A · Market cap: $791.4M